TECHNOLOGY OVERVIEW: PHARMACEUTICALS
|
|
- Ralf Pierce Beasley
- 5 years ago
- Views:
Transcription
1 TECHNOLOGY OVERVIEW: PHARMACEUTICALS ISSUE 3.1 JUNE 1996 PHARMACEUTICAL MANAGEMENT OF PEPTIC ULCER DISEASE prepared by Ms. Christine Perras, BSc Phm Pharmaceutical Associate, CCOHTA and Dr. Nicolaas Otten, Pharm D. Coordinator, Pharmaceutical Assessment, CCOHTA This overview has been prepared by staff at the Canadian Coordinating Office for Health Technology Assessment (CCOHTA) and is based in part on a study commissioned by CCOHTA: Cost-effectiveness of alternative therapies for the long-term management of peptic ulcer disease conducted by Dr. Bernie O'Brien (McMaster University/St. Joseph's Hospital, Hamilton, Ontario), Mr. Ron Goeree (McMaster University/St. Joseph's Hospital, Hamilton, Ontario), Dr. Richard Hunt (McMaster University, Hamilton, Ontario), Ms. Joanne Wilkinson (McMaster University, Hamilton, Ontario), Dr. Mitchell Levine (McMaster University/St. Joseph's Hospital, Hamilton, Ontario), Dr. Andrew Willan (McMaster University, Hamilton, Ontario). The overview has been reviewed and accepted by CCOHTA's Scientific Advisory Panel. It does not necessarily reflect the opinions of the Panel, the Board of CCOHTA or the investigators.
2 Additional copies of Pharmaceutical Management of Peptic Ulcer Disease are available from CCOHTA. Vous pouvez aussi vous procurer la version française à l OCCETS. Reproduction of this document for non-commercial purposes is permitted provided appropriate credit is given to CCOHTA. Legal Deposit National Library of Canada ISSN Approximately 10% of the adult population will suffer from peptic ulcer disease (PUD) at some point in their life. Most individuals experiencing heartburn after eating, self-medicate with antacids, consulting a physician only if symptoms are not relieved. H 2 antagonists are usually prescribed as first line therapy, with ranitidine being the most widely prescribed. However, the use of omeprazole is increasing steadily due in part to increasing evidence of its efficacy, in combination with antimicrobials, for the eradication of Helicobacter pylori (H.pylori). A study commissioned by CCOHTA entitled Cost-effectiveness of alternative therapies for the long-term management of peptic ulcer disease 1 evaluates different drug treatment strategies available for the management of patients with PUD. Specifically, the study compares maintenance ranitidine to treatment of acute ulcer with omeprazole or ranitidine, as well as H.pylori eradication regimens. This overview attempts to put the findings of the commissioned study into clinical perspective.
3 CONCLUSIONS PHARMACEUTICAL MANAGEMENT OF PEPTIC ULCER DISEASE 1) All H 2 antagonists have similar ulcer healing rates. 2) There are too few studies available to evaluate differences between omeprazole and the new proton pump inhibitor (PPI) lansoprazole. 3) Of the two acute ulcer healing regimens (intermittent omeprazole and intermittent ranitidine), intermittent omeprazole is the most effective and the least costly option. 4) The H.pylori eradication regimens are more effective (increased rate of healing and decreased recurrences) than either treating only the acute ulcer episodes or providing maintenance ranitidine. In terms of direct health care costs, four of the six regimens cost less per patient per year and have better outcomes than maintenance ranitidine. 5) Of the H.pylori eradication regimens, ranitidine-bismuth triple therapy is the least expensive but also the least effective. Omeprazole in combination with two antibiotics decreases the time with ulcer by 12 to 13 days compared to the ranitidine-bismuth triple therapy but at an extra cost ranging from $64 to $108 per patient per year. 6) Study limitations include the use of efficacy data and expert opinions instead of effectiveness studies. Also, a Ministry of Health perspective is taken instead of a societal one. 7) The results of the commissioned study are comparable to those conducted in other countries 2,3,4 with H.pylori eradication regimens being the most effective therapy for PUD. Canadian Coordinating Office for Health Technology Assessment 1
4 INTRODUCTION PHARMACEUTICAL MANAGEMENT OF PEPTIC ULCER DISEASE Duodenal ulcers and gastric ulcers are the most common forms of peptic ulcer disease. It is estimated that approximately 10% of adults will have PUD at some point in their life. Individuals experiencing burning pain after eating will frequently self-medicate with over-the-counter (OTC) medications such as antacids. They will usually seek medical care when symptoms are persistent or no longer relieved by OTC medications. Standard treatment for PUD has traditionally been based on acid suppression using treatment modalities such as antacids, sucralfate, H 2 antagonists (eg.cimetidine), proton pump inhibitors (eg.omeprazole) and surgery. Evidence is accumulating showing that strategies aimed at eradicating H.pylori (eg.antimicrobials with acid suppressing drugs) produce favorable healing rates and greater reduction in rates of ulcer recurrences. Given that omeprazole's use is increasing steadily and that treatment strategies are changing due to our current knowledge of the role of H. pylori in PUD, it remains to be determined what is the best therapeutic modality. The commissioned study evaluates the different drug treatment strategies for the management of patients with confirmed and uncomplicated peptic ulcers. Specifically, the study compares maintenance ranitidine to treatment of acute ulcer with omeprazole or ranitidine, as well as H.pylori eradication regimens, and relates the findings in a pharmacoeconomic evaluation. The study also evaluates whether efficacy is different among the various H 2 antagonists as well as between the two available PPIs. EFFICACY/ EFFECTIVENESS There have been many clinical trials to date comparing the various treatment regimens used in the management of duodenal ulcers. Recently, focus has been on H.pylori eradication therapy. It is beyond the scope of this paper to present all relevant randomized clinical trials. The model used in the commissioned study is based on results obtained in randomized controlled trials and expert opinions in non-drug management. The primary outcome of interest is the amount of time the patient can be expected to be free from ulcer in one year. This amount of time is calculated based on the healing time and the likelihood of recurrences. Ulcer healing probabilities are obtained by pooling results of randomized controlled trials, specifically in adults with duodenal ulcer where healing is confirmed by endoscopy at set intervals. Weeks with ulcer per acute healing episode are derived from these probabilities (Table 1). H 2 antagonists, PPIs and six different eradication regimens are being compared. The different H 2 antagonists available are: cimetidine, famotidine, nizatidine and ranitidine. An evaluation done in the commissioned study shows that there is very little difference between these four drugs in terms of rates of healing and recurrences. Ranitidine is the most widely prescribed H 2 antagonist and is used in the base case analysis. Similarly, omeprazole is used instead of lansoprazole. Variations in the drug prices are addressed in sensitivity analyses. 2 Canadian Coordinating Office for Health Technology Assessment
5 PHARMACEUTICAL MANAGEMENT OF PEPTIC ULCER DISEASE TABLE 1: Ulcer Healing Probabilities and Weeks with Ulcer Drug Total daily dose % healed at 2 weeks % healed at 4 weeks % healed at 8 weeks # weeks with ulcer a Ranitidine 300mg -- 72% (CI b :67-76) 86% (CI:84-89) 3.4 a b Omeprazole 20mg 64% (CI:60-68) 87% (CI:85-89) time horizon is 8 weeks for ranitidine and 4 weeks for omeprazole CI denotes 95% confidence interval Table 2 gives H.pylori eradication probabilities for strategies involving omeprazole and antibiotics (probabilities are based on results of a previously published meta-analysis 5 ) and for the ranitidinebismuth triple therapy (the probability of eradication is obtained by pooling the results of clinical trials). TABLE 2: H. pylori Eradication Probabilities Drug Regimen % Eradication omeprazole and amoxicillin (O+A) 61% (CI: 57-66) omeprazole and clarithromycin (O+C) 71% (CI: 66-76) omeprazole, amoxicillin and metronidazole (O+A+M) 84% (CI: 79-90) omeprazole, amoxicillin and clarithromycin (O+A+C) 85% (CI: 75-96) omeprazole, clarithromycin and metronidazole (O+C+M) 91% (CI: 88-94) ranitidine-bismuth triple therapy (ranitidine, bismuth subsalicylate, metronidazole and tetracycline; Ran-BMT) 86% (CI: 80-92) Probabilities of ulcer recurrence (Table 3) are determined from randomized double-blind trials in adults, diagnosed by endoscopy at 6 months, 12 months or both, for placebo, maintenance ranitidine therapy and pooled H.pylori eradication regimens. TABLE 3: Ulcer Recurrence Probabilities Drug Regimen % Recurrence a 0-6 months % Recurrence b 6-12 months a b c Placebo 56% (CI: 40-72) 18% (CI: 6-29) Ranitidine 150mg daily 12% (CI: 6-19) 12% (CI: 3-21) H.pylori eradication c -unsuccessful -successful 53% (CI: 36-69) 4% (CI: 0-11) 46% (CI: 31-61) 1% (CI: 0-10) probability of recurrence anytime during the first six months probability of recurrence in patients not experiencing a recurrence during the first six months some patients will remain positive for H.pylori following eradication treatment and as seen above, will be more likely to experience a recurrence Canadian Coordinating Office for Health Technology Assessment 3
6 PHARMACEUTICAL MANAGEMENT OF PEPTIC ULCER DISEASE A seven-year follow-up study 6 also showed a small probability of ulcer recurrence (3%) in patients who tested negative for H. pylori following eradication therapy, supporting the results of the meta-analysis. Evaluation of 35 trials revealed that 76% of ulcer recurrences are symptomatic. Only symptomatic recurrences are used in the model. PARAMETERS OF THE EVALUATION a) Perspective/Target Audience The perspective adopted reflects the target audience which is the Ministry of Health. In addition, physicians, formulary managers and patients may find the analysis to be relevant. b) Treatment Comparators Three therapeutic strategies are being compared. The drugs, dosages as well as length of therapy are described in detail in the section on costs. 1) Ulcer is healed with an H 2 antagonist or with a PPI. Maintenance therapy is not initiated. Recurrences are treated with the same agent as used previously. 2) Ulcer is healed with an H 2 antagonist followed by continuous half dose maintenance therapy with the same H 2 antagonist. Recurrences are treated with the same agent. 3) Ulcer is healed and H. pylori eradicated using one of six possible regimens: omeprazole and amoxicillin; omeprazole and clarithromycin; omeprazole, metronidazole and amoxicillin; omeprazole, amoxicillin and clarithromycin; omeprazole, clarithromycin and metronidazole; or, an H 2 antagonist and bismuth triple therapy. Recurrences are treated with an H 2 antagonist. c) Time Horizon The time horizon is a one-year period from the time of diagnosis of PUD. d) Cost Elements of Interest Direct costs accruing to the health care system are used. (See "Costs" below). COSTS Drug costs (Table 4) are obtained from the Ontario Drug Benefit Plan (best available price plus 10% pharmacy upcharge) or from a survey of local pharmacies for drugs not covered under the Ontario drug plan. 4 Canadian Coordinating Office for Health Technology Assessment
7 PHARMACEUTICAL MANAGEMENT OF PEPTIC ULCER DISEASE TABLE 4: Costs of Drug Regimens a Regimen Description Cost Intermittent ranitidine Intermittent omeprazole Maintenance ranitidine O+A O+C O+A+M O+A+C O+C+M treatment: ranitidine 150mg BID x 8 weeks maintenance: none treatment of recurrence: same as treatment treatment: omeprazole 20mg daily x 28 days maintenance: none treatment of recurrence: same as treatment treatment: ranitidine 150mg BID x 8 weeks maintenance: ranitidine 150 mg daily treatment of recurrence: same as treatment omeprazole 20mg BID x 14 days and amoxicillin 1g BID x 14 days; omeprazole 20mg daily on days omeprazole 20mg BID x 14 days and clarithromycin 500mg TID x 14 days; omeprazole 20mg daily on days omeprazole 20mg BID x 14 days and amoxicillin 1g BID x 7 days and metronidazole 500mg BID x 7 days; omeprazole 20mg OD on days 14 to 28. omeprazole 20mg BID x 14 days and clarithromycin 500mg BID x 7 days and amoxicillin 1g BID x 7 days; omprazole 20mg OD on days 14 to 28. omeprazole 20mg BID x 14 days and clarithromycin 500mg BID x 7 days and metronidazole 500mg BID x 7 days; omeprazole 20mg OD on days 14 to 28. $50.40 $0.00 $50.40 $71.96 $0.00 $71.96 $50.40 $0.45/day $50.40 $ $ $ $ $ a Ran-BMT ranitidine 150mg BID x 56 days; bismuth subsalicylate 151mg QID on days 42 to 56 metronidazole 250mg QID on days 42 to 56 tetracycline 500mg QID on days 42 to 56. excludes dispensing fees; based on generic prices when generic drug is available $66.08 Note: All ulcer recurrences following treatment for H.pylori are treated with ranitidine 150mg twice daily for 8 weeks. Unit prices for health care resources utilized in the management of duodenal ulcers (excluding drugs) are based on costs obtained from the physician fee schedule for Ontario and from Chedoke-McMaster Hospital in Hamilton, Ontario. Based on clinical opinions obtained from an expert physician panel convened to identify resources used by patients presenting with symptoms of ulcer recurrences, it costs $ and $ per patient to treat first and second recurrences respectively in patients treated with intermittent omeprazole, intermittent ranitidine or maintenance ranitidine (excluding cost of drugs). For patients treated with one of eradication strategies, it costs $ and $ per patient to treat first and second recurrences respectively (excluding cost of drugs). Canadian Coordinating Office for Health Technology Assessment 5
8 PHARMACEUTICAL MANAGEMENT OF PEPTIC ULCER DISEASE RESULTS TABLE 5: Expected Outcomes and Total Costs in One Year Regimen Expected Weeks with Recurrences per 100 Ulcer per Patient a Patients b Expected Cost per Patient c Intermittent ranitidine 5.7 (CI: ) 69 (CI: 43-95) $306 (CI: ) Intermittent omeprazole 3.1 (CI: ) 69 (CI: 43-95) $343 (CI: ) Maintenance ranitidine 4.0 (CI: ) 18 (CI: 7-30) $353 (CI: ) O+A 2.4 (CI: ) O+C 2.3 (CI: ) O+A+M 2.1 (CI: ) O+A+C 2.1 (CI: ) O+C+M 2.0 (CI: ) 28 (CI: 18-42) 22 (CI: 13-36) 14 (CI: 7-27) 13 (CI: 7-26) 10 (CI: 4-22) $387 (CI: ) $482 (CI: ) $292 (CI: ) $337 (CI: ) $306 (CI: ) a b c Ran-BMT 3.8 (CI: ) includes time with ulcer and time with recurrences symptomatic recurrences only 12 (CI: 6-25) includes all costs of treating an acute episode and any recurrences in one year $228 (CI: ) Note: CI is 95% confidence interval based on a one-way sensitivity analysis on ulcer recurrence probabilities. 1) Cost The ranitidine-bismuth triple therapy combination (Ran-BMT) has the lowest cost per patient per year. The omeprazole-clarithromycin and the omeprazole-amoxicillin combinations (O+C and O+A) are the most expensive treatments even compared to the cost of omeprazole plus two antibiotics over one year. The reasons for the high cost are the higher recurrence rates and the difference in dosing (clarithromycin is given three times daily for 14 days in strategy O+C compared to twice daily for 7 days in strategies O+A+C and O+C+M). 2) Efficacy Time with ulcer: The eradication regimens combining omeprazole with two antibiotics (O+A+M, O+A+C and O+C+M) have the shortest times with ulcer. Recurrence rate: Omeprazole in combination with two antibiotics (O+A+M, O+A+C and O+C+M) as well as the ranitidine-bismuth triple therapy offer the lowest rate of recurrences. 6 Canadian Coordinating Office for Health Technology Assessment
9 PHARMACEUTICAL MANAGEMENT OF PEPTIC ULCER DISEASE Considering both time with ulcer and recurrence rate, omeprazole in combination with two antibiotics (O+A+M, O+A+C and O+C+M) show the greatest overall benefit. 3) Cost-effectiveness The cost-effectiveness analysis incorporates clinical outcomes and the costs associated with treating the ulcer and any recurrences in one year (Table 6). TABLE 6: Cost-effectiveness of all Regimens Relative to Maintenance Ranitidine Regimen Expected Cost per Patient in one Year Time-free from ulcer (weeks) C ($) E (weeks) Costeffectiveness Intermittent ranitidine Intermittent omeprazole Maintenance ranitidine $ lower cost but lower efficacy $ D* $ O+A $ higher cost for higher effect O+C $ higher cost for higher effect O+A+M $ D* O+A+C $ D* O+C+M $ D* Ran-BMT $ D* D*=dominant strategies: less cost for more effect, compared to maintenance ranitidine Of the two acute ulcer healing regimens (intermittent omeprazole and intermittent ranitidine), intermittent omeprazole is the most effective and the least costly option. All the H.pylori eradication regimens are more effective than treating only the acute ulcer episodes or using maintenance ranitidine strategy to prevent further ulcer. 4) Comparing the H.pylori eradication regimens! the omeprazole-antimicrobial combinations have similar disease-free periods;! the omeprazole-clarithromycin and the omeprazole-amoxicillin combinations are the most expensive options and the ranitidine-bismuth triple therapy is the least expensive option;! omeprazole in combination with two antibiotics decrease the time with ulcer by 12 to 13 days compared to the ranitidine-bismuth triple therapy but at an extra cost ranging from $64 to $108 per patient per year. Canadian Coordinating Office for Health Technology Assessment 7
10 PHARMACEUTICAL MANAGEMENT OF PEPTIC ULCER DISEASE Substituting maintenance ranitidine with ranitidine-bismuth triple therapy (Ran-BMT) results in cost-savings of $125,000 and 200 extra weeks of ulcer-free time per 1,000 patients in a one-year period. Using the omeprazole, amoxicillin and metronidazole combination (O+A+M) instead of maintenance ranitidine offers an additional 1,700 weeks of ulcer-free time per 1,000 patients in a one-year period but with lower costsavings of $61,000. Variations in drug prices across the different provinces do not alter the ranking of these options. 5) Study limitations: Clinical Randomized controlled trials require participants to be diagnosed by endoscopy or require a biopsy or test to determine their H.pylori status. In actual practice, a large proportion of patients presenting with epigastric pain will be treated empirically. Similarly, outcome of treatment may not always be confirmed by endoscopy or biopsy. Weeks with ulcer does not necessarily correlate to weeks with symptoms. Most patients enter an asymptomatic state (patient no longer suffers from epigastric pain) but are still not cured. The commissioned study does not consider patients with ulcers secondary to non steroidal antiinflammatory agents, patients with complicated ulcers such as bleeding ulcers, or ulcers extending into the esophagus, although these represent less than 10% of the ulcer patient population. The commissioned study does not consider the side effects associated with the different drugs. The commissioned study does not take patient compliance into consideration. Concerns have been raised that the H.pylori eradication regimens may be too complex for patients to follow. However, very few H.pylori eradication studies have evaluated patient compliance as part of the clinical trial. Resistance to antibiotics is a concern and has been linked to treatment failures in some studies. This problem may become more important with the increase use of antimicrobials in the treatment of PUD. Other therapeutic modalities are being considered (eg.h.pylori vaccines) to address this concern. 6) Study limitations: Economic The commissioned study uses a model based on data obtained from randomized controlled trials (rates of ulcer healing, recurrences and eradication) and on expert physicians' opinions (use of resources for ulcer recurrence) rather than studies based on actual clinical practice (effectiveness studies) to derive its findings. Due to patient selection and small sample size in some trials, randomized controlled trials results need to be interpreted with caution when extrapolated to the general population. The commissioned study takes a health care perspective and only includes direct costs. The impact on patients' lifestyle (eg.work absenteeism) and as such on society, is not evaluated. The cost associated with treating an ulcer and its recurrence (excluding drugs) are obtained from the Ontario physician fee schedule and an hospital in Hamilton, Ontario. These costs may not reflect those of other provinces or institutions. The commissioned study does not consider the costs associated with the management of complications. Although these are rare, they are usually expensive. 8 Canadian Coordinating Office for Health Technology Assessment
11 ENDNOTES PHARMACEUTICAL MANAGEMENT OF PEPTIC ULCER DISEASE 1 O'Brien, B., Goeree, R., Hunt, R., Wilkinson, J., Levine, M., Willan, A. (1996). Cost-effectiveness of alternative therapies for the long-term management of peptic ulcer disease. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA). 2 Sonnenberg, A., Townsend, W.F. (1995). Costs of duodenal ulcer therapy with antibiotics. Archives of Internal Medicine;155: Unge, P., Jonsson, B., Stalhammar, N. (1995). The cost effectiveness of Helicobacter pylori eradication versus maintenance and episodic treatment in duodenal ulcer patients in Sweden. PharmacoEconomics;8(5): Philips, C.,Moore, A. (1996). Implementing evidence-based medical interventions: the costeffectiveness of Helicobacter pylori diagnosis and eradication. British Medical Journal of Medical Economics;10: Chiba, N., Wilkinson, J.M., Hunt, R.H. (1995). Clarithromycin or amoxicillin dual and triple therapies in H.pylori eradication: A meta-analysis. Gut;37:A31. 6 Forbes, G.M., Glaser, M.E., Cullen, D.J., Warren, J.R., Christiansen, K.J., Marshall, B.J. (1994) Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet;343: Previous drafts of the technical document Cost-effectiveness of alternative therapies for the long-term management of peptic ulcer disease were reviewed by the Scientific Advisory Panel of CCOHTA: Dr. Andreas Laupacis Dr. David Feeny Dr. Lawrence Joseph Dr. Roy West Dr. Raisa Deber Dr. Heather Bryant Comments were also received from: Dr. Lloyd Sutherland Astra Pharma Inc. Eli Lilly Canada Janssen-Ortho Inc. Procter and Gamble Pharma Ottawa Civic Hospital McMaster University McGill University Memorial University University of Toronto University of Calgary University of Calgary CCOHTA would like to thank the above for their contributions. The complete report Cost-effectiveness of alternative therapies for the long-term management of peptic ulcer disease is available by contacting CCOHTA. Please address all enquiries and correspondence to: Publications, CCOHTA, Green Valley Crescent, Ottawa, Ontario, Canada, K2C 3V4. Tel.: (613) ; Fax: (613) ; pubs@ccohta.ca. Canadian Coordinating Office for Health Technology Assessment 9
12 Canadian Coordinating Office for Health Technology Assessment Green Valley Crescent Ottawa, Ontario, Canada K2C 3V4
PHARMACEUTICALS ISSUE 2.0 APRIL 1996 FINASTERIDE: CLINICAL AND ECONOMIC IMPACTS
TECHNOLOGY OVERVIEW: PHARMACEUTICALS ISSUE 2.0 APRIL 1996 FINASTERIDE: CLINICAL AND ECONOMIC IMPACTS prepared by Dr. Nicolaas Otten, Pharm D. Coordinator, Pharmaceutical Assessment, CCOHTA This overview
More informationTECHNOLOGY OVERVIEW: PHARMACEUTICALS
TECHNOLOGY OVERVIEW: PHARMACEUTICALS ISSUE 8.0 OCTOBER 1997 MACROLIDES IN COMMUNITY-ACQUIRED PNEUMONIA AND OTITIS MEDIA based primarily on the Technical Report: A Therapeutic and Economic Evaluation of
More informationTECHNOLOGY OVERVIEW: PHARMACEUTICALS
TECHNOLOGY OVERVIEW: PHARMACEUTICALS ISSUE 9.0 DECEMBER 1997 THE USE OF G-CSF IN THE PREVENTION OF FEBRILE NEUTROPENIA based primarily on the Technical Report : The Cost-Effectiveness of G-CSF for Prophylaxis
More informationTECHNOLOGY OVERVIEW: PHARMACEUTICALS
TECHNOLOGY OVERVIEW: PHARMACEUTICALS ISSUE 4.0 DECEMBER 1996 THE USE OF NITRATES IN CHRONIC STABLE ANGINA prepared by Ms. Christine Perras, BSc Phm Pharmaceutical Associate, CCOHTA This overview has been
More informationHelicobacter 2008;13:1-6. Am J Gastroent 2007;102: Am J of Med 2004;117:31-35.
An Update on Helicobacter pylori and Its Treatment Trenika Mitchell, PharmD, BCPS Clinical Assistant Professor University of Kentucky College of Pharmacy October 18, 2008 Objectives Review the epidemiology
More informationMANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Routine endoscopic investigation of patients of any age, presenting with dyspepsia
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationPharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W
Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori Taylor J L, Zagari M, Murphy K, Freston J W Record Status This is a critical abstract of an economic evaluation that
More informationGASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA
GASTROINTESTINAL SYSTEM MANAGEMENT OF DYSPEPSIA MANAGEMENT Dyspepsia refers to a spectrum of usually intermittent upper gastrointestinal symptoms, including epigastric pain and heartburn. For the majority
More informationStudy population The study population comprised hypothetical patients with gastric and duodenal ulcer.
Evaluation of the cost-effectiveness of Helicobacter pylori eradication triple therapy vs. conventional therapy for ulcers in Japan Ikeda S, Tamamuro T, Hamashima C, Asaka M Record Status This is a critical
More informationDERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) MANAGEMENT OF DYSPEPSIA o Patients of any age with ALARM signs should be referred through the 2-week referral system o Routine endoscopic investigation
More informationManagement of dyspepsia and of Helicobacter pylori infection
Management of dyspepsia and of Helicobacter pylori infection The University of Nottingham John Atherton Wolfson Digestive Diseases Centre University of Nottingham, UK Community management of dyspepsia
More informationProton Pump Inhibitors Drug Class Prior Authorization Protocol
Proton Pump Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: November 15, 2017 Effective Date: January 1, 2018 This policy has been developed through review
More informationACG Clinical Guideline: Treatment of Helicobacter pylori Infection
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection William D. Chey, MD, FACG 1, Grigorios I. Leontiadis, MD, PhD 2, Colin W. Howden, MD, FACG 3 and Steven F. Moss, MD, FACG 4 1 Division
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 5 March 2007 Current Practice Analysis Report for the Prescribing and Use of Proton Pump Inhibitors (PPIs) Supporting Informed Decisions À l appui des décisions
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 6 March 2007 Gap Analysis Report for the Prescribing and Use of Proton Pump Inhibitors (PPIs) Supporting Informed Decisions À l appui des décisions éclairées
More informationGuidelines for the Management of Dyspepsia and GORD. Gastroenterology/ Acute Adult Governance. Drugs and Therapeutics Committee
Guidelines for the Management of Dyspepsia and GORD Document type: Version: 3.0 Author (name): Author (designation): Validated by Prescribing Dr. G. Lipscomb Date validated October 2015 Ratified by: Date
More informationDrug Class Monograph
Drug Class Monograph Class: Proton Pump Inhibitors Drugs: Aciphex Sprinkle (rabeprazole), Dexilant (dexlansoprazole), Lansoprazole, Nexium (esomeprazole capsule, esomeprazole granules), Omeprazole, Pantoprazole,
More informationHigh use of maintenance therapy after triple therapy regimes in Ireland
High use of maintenance therapy after triple therapy regimes in Ireland K Bennett, H O Connor, M Barry, C O Morain, J Feely Department of Pharmacology & Therapeutics Department of Gastroenterology Trinity
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées. Proton Pump Inhibitor Project Overview: Summaries
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 1 March 2007 Proton Pump Inhibitor Project Overview: Summaries Supporting Informed Decisions À l appui des décisions éclairées This Executive Summary is based
More informationPrevpac Pylera Omeclamox-Pak
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.21 Subject: -Pak Page: 1 of 5 Last Review Date: September 20, 2018 -Pak Description (lansoprazole,
More informationCHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS. 1. Which of the following is not a common cause of peptic ulcer disease (PUD)?
CHAPTER 18. PEPTIC ULCER DISEASE, SELF-ASSESSMENT QUESTIONS 1. Which of the following is not a common cause of peptic ulcer disease (PUD)? A. Chronic alcohol ingestion B. Nonsteroidal antiinflammatory
More informationSetting The setting was primary care. The economic study was conducted in Canada.
Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment - Helicobacter pylori positive (CADET-Hp) randomised controlled
More informationPeptic Ulcer Disease Update
Peptic Ulcer Disease Update Col Pat Storms RAM 2005 Disclosure Information 84th Annual AsMA Scientific Meeting Col Patrick Storms I have no financial relationships to disclose. I will discuss the following
More informationPeptic ulcer disease Disorders of the esophagus
Peptic ulcer disease Disorders of the esophagus Peptic ulcer disease Burning epigastric pain Exacerbated by fasting Improved with meals Ulcer: disruption of mucosal integrity >5 mm in size, with depth
More informationProton Pump Inhibitors (PPIs) (Sherwood Employer Group)
Proton Pump Inhibitors (PPIs) (Sherwood Employer Group) BCBSKS will review Prior Authorization requests Prior Authorization Form: https://www.bcbsks.com/customerservice/forms/pdf/priorauth-6058ks-st-ippi.pdf
More informationHelicobacter pylori. Objectives. Upper Gastrointestinal Bleeding Peptic Ulcer Disease
Upper Gastrointestinal Bleeding Peptic Ulcer Disease Pharmacotherapy Issues in Acute Management and Secondary Prevention Peter J. Zed, B.Sc., B.Sc.(Pharm), Pharm.D. Pharmacotherapeutic Specialist - Emergency
More informationCOMPUS OPTIMAL THERAPY REPORT. Supporting Informed Decisions. À l appui des décisions éclairées. Proton Pump Inhibitor Project Overview: Summaries
OPTIMAL THERAPY REPORT COMPUS Volume 1, Issue 1 March 2007 Proton Pump Inhibitor Project Overview: Summaries Supporting Informed Decisions À l appui des décisions éclairées This Executive Summary is based
More informationSELECTED ABSTRACTS. Figure. Risk Stratification Matrix A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY
SELECTED ABSTRACTS A CLINICIAN S GUIDE TO THE SELECTION OF NSAID THERAPY The authors of this article present a 4-quadrant matrix based on 2 key clinical parameters: risk for adverse gastrointestinal (GI)
More informationPharmacoeconomic analysis of proton pump inhibitor therapy and interventions to control Helicobacter pylori infection Klok, Rogier Martijn
University of Groningen Pharmacoeconomic analysis of proton pump inhibitor therapy and interventions to control Helicobacter pylori infection Klok, Rogier Martijn IMPORTANT NOTE: You are advised to consult
More informationPRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW
PRESCRIBING SUPPORT TEAM AUDIT: PROTON PUMP INHIBITOR PRESCRIBING REVIEW DATE OF AUTHORISATION: AUTHORISING GP: PRESCRIBING SUPPORT TECHNICIAN: SUMMARY Dyspepsia refers to a broad range of symptoms related
More informationManagement of Dyspepsia
MPharm Programme Management of Dyspepsia Slide 1 of 28 Learning Objectives Understand the principles and wider implications underpinning evidence based therapeutics in the key clinical specialities Objectively
More informationHealth technology The use of four different combined treatments for Helicobacter pylori (H. pylori) infection. These were:
Tratamiento de la infeccion por Helicobacter pylori en pacientes con ulcera duodenal: estudio de costo-beneficio [Treatment of Helicobacter pylori infection in patients with duodenal ulcer: a cost-benefit
More informationRpts. GENERAL General Schedule (Code GE) Program Prescriber type: Dental Medical Practitioners Nurse practitioners Optometrists Midwives
Esomeprazole 20mg Name, Restriction, Manner of esomeprazole 20 mg enteric tablet, 30 (8886Q) (029W) Gastric ulcer Peptic ulcer Treatment Phase: Initial treatment The therapy must be for initial treatment
More informationCase 4: Peptic Ulcer Disease. Requejo, April Salandanan, Geralyn Talingting, Vennessa Tanay, Arvie
Case 4: Peptic Ulcer Disease Requejo, April Salandanan, Geralyn Talingting, Vennessa Tanay, Arvie Case 4: PUD Problem List: 1. Peptic Ulcer Disease SOAP Note: S Patient is complaining of abdominal pain
More informationAll Indiana Medicaid Prescribers and Pharmacy Providers
P R O V I D E R B U L L E T I N BT200148 NOVEMBER 28, 2001 To: All Indiana Medicaid Prescribers and Pharmacy Providers Subject: Note: The information in this bulletin regarding prior authorization payment
More informationTreating H. pylori in 2016
Treating H. pylori in 2016 William D. Chey, MD, FACG Professor of Medicine University of Michigan The Case: A 38 yo Russian man presents with recurrent epigastric pain which occurs after meals and sometimes
More informationSetting The setting was primary care. The economic analysis was conducted in Glasgow, UK.
Helicobacter pylori eradication for peptic ulceration: an observational study in a Scottish primary care setting Forrest E H, MacKenzie J F, Stuart R C, Morris A J Record Status This is a critical abstract
More informationOriginal Policy Date
MP 2.04.38 Genetic Testing for Helicobacter pylori Treatment Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return
More informationSource of effectiveness data The effectiveness data were derived from a review and synthesis of completed studies.
Economic evaluation of maintenance therapies for reflux esophagitis: comparison between step-up therapies and step-down therapies Sugano K, Kobayashi M Record Status This is a critical abstract of an economic
More informationSetting The setting was community. The economic study was carried out in the USA.
Costs of managing Helicobacter pylori-infected ulcer patients after initial therapy Griffiths R I, Rabeneck L, Guzman G, Cromwell D M, Strauss M J, Robinson J W, Winston B, Li T, Graham D Y Record Status
More informationWhat is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori?
What is the status of Sequential Therapy Versus Standard Triple- Drug Therapy in peptic ulcer disease in eradicating H pylori? Sequential Therapy Versus Standard Triple- Drug Therapy for Helicobacter pylori
More informationCost-effectiveness analysis of different strategies for treating duodenal ulcer Badia X, Segu J L, Olle A, Brosa M, Mones J, Ponte L G
Cost-effectiveness analysis of different strategies for treating duodenal ulcer Badia X, Segu J L, Olle A, Brosa M, Mones J, Ponte L G Record Status This is a critical abstract of an economic evaluation
More informationTreatment of Helicobacter pylori Infection
Treatment of Helicobacter pylori Infection Epidemiology of H. pylori infection (North America) Which are the high risk groups? Epidemiology of H. pylori infection (North America) Which are the high risk
More informationOmeprazole 10mg. Name, Restriction, Manner of administration and form OMEPRAZOLE omeprazole 10 mg enteric tablet, 30 (8332M) Max. Qty.
Omeprazole 10mg Name, Restriction, Manner of administration and form omeprazole 10 mg enteric tablet, 30 (8332M) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form omeprazole
More informationNational Digestive Diseases Information Clearinghouse
Gastritis National Digestive Diseases Information Clearinghouse U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH What is gastritis? Gastritis is a condition in which the stomach
More informationa newsletter detailing appropriate indications of IV PPI was sent to physicians;
Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions Kaplan G G, Bates D, McDonald D, Panaccione R, Romagnuolo J Record Status This is a critical abstract of an
More informationDeveloping Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada
Developing Evidence-Based Best Practices for the Prescribing and Use of Proton Pump Inhibitors in Canada Presented by: Sumeet R. Singh, COMPUS April 4, 2006 Background COMPUS Objective: To identify and
More informationCopy right protected Page 1
DRUGS USED IN ULCERS AND GIT DISORDERS A peptic ulcer, also known as PUD or peptic ulcer disease is an ulcer of an area of the gastrointestinal tract that is usually acidic and thus extremely painful.
More informationAlternative management strategies for patients with suspected peptic ulcer disease Fendrick M A, Chernew M E, Hirth R A, Bloom B S
Alternative management strategies for patients with suspected peptic ulcer disease Fendrick M A, Chernew M E, Hirth R A, Bloom B S Record Status This is a critical abstract of an economic evaluation that
More informationKK College of Nursing Peptic Ulcer Badil D ass Dass, Lecturer 25th July, 2011
KK College of Nursing Peptic Ulcer Badil Dass, Lecturer 25 th July, 2011 Objectives: By the end of this lecture, the students t will be able to: Define peptic pp ulcer Describe the etiology and pathology
More informationMacrolides in community-acquired pneumonia and otitis media Canadian Coordinating Office for Health Technology Assessment
Macrolides in community-acquired pneumonia and otitis media Canadian Coordinating Office for Health Technology Assessment Record Status This is a critical abstract of an economic evaluation that meets
More informationTreatment with PPIs for Patients with GERD Symptoms
9. Treatment with PPIs for Patients with GERD Symptoms How long should you consider continuing treatment with PPIs for patients with gastroesophageal reflux disease (GERD) symptoms? Dr. H. Ayad Pinawa,
More informationSetting The setting was secondary care. The economic study was carried out in Hong Kong, China.
Cost-effectiveness of Helicobacter pylori "test and treat" for patients with typical reflux symptoms in a population with a high prevalence of H. pylori infection: a Markov model analysis You J H, Wong
More informationSetting The setting was primary care. The economic study was carried out in Canada.
Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H-pylori-positive primary care patients with uninvestigated dyspepsia Chiba N, Van Zanten S J, Escobedo
More informationGastro-oesophageal reflux disease and peptic ulcer disease. By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D
Gastro-oesophageal reflux disease and peptic ulcer disease By: Dr. Singanamala Suman Assistant Professor Department of Pharm.D Gastro-oesophageal reflux disease and peptic ulcer disease Learning objectives:
More informationOm epr azole, am ox icillin, clarithr omycin H elicobacter p y lori
: 58 6 2000 Om epr azole, am ox icillin, clarithr omycin H elicobacter p y lori, =A b s t r a c t s = T he e f f e ct of He lic obac te r p y lo ri eradic ation of triple therapy w ith ome prazole, am
More informationManagement of dyspepsia in adults in primary care
Dyspepsia Management of dyspepsia in adults in primary care June 2005. The recommendations on referral for endoscopy in this NICE guideline have been amended in line with the recommendation in the NICE
More informationTECHNOLOGY OVERVIEW: PHARMACEUTICALS
TECHNOLOGY OVERVIEW: PHARMACEUTICALS ISSUE 7.0 JULY 1997 PHARMACOECONOMIC EVALUATIONS OF CLOZAPINE IN TREATMENT-RESISTANT SCHIZOPHRENIA AND RISPERIDONE IN CHRONIC SCHIZOPHRENIA prepared by Dr. Judith L.
More informationAccepted Manuscript. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults
Accepted Manuscript The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults Carlo A. Fallone, Naoki Chiba, Sander Veldhuyzen van Zanten, Lori Fischbach, Javier P. Gisbert, Richard
More informationGeneral practice. Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model.
Varying efficacy of Helicobacter pylori eradication regimens: cost effectiveness study using a decision analysis model A E Duggan, K Tolley, C J Hawkey, R F A Logan Department of Public Health and Epidemiology,
More informationProton Pump Inhibitors. Description. Section: Prescription Drugs Effective Date: July 1, 2014
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.09.01 Subject: Proton Pump Inhibitors Page: 1 of 7 Last Review Date: June 12, 2014 Proton Pump Inhibitors
More informationHealth Economics 101: PPI prescriptions in the Emergency Room
: PPI prescriptions in the Emergency Room Canadian Optimal Medication Prescribing & Utilization Service (COMPUS) Presented by: Chris Cameron October 26, 2007 What is Health Economics? Health economics
More informationSELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) FOR MAJOR DEPRESSION
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs) FOR MAJOR DEPRESSION PART II THE COST-EFFECTIVENESS OF SSRIs IN TREATMENT OF DEPRESSION CCOHTA Report 1997: 4E The (CCOHTA) is a non-profit organization,
More informationSummary of Findings on the Prescribing and Use of Proton Pump Inhibitors. COMPUS Interim Report CCOHTA. March 6, 2006
Summary of Findings on the Prescribing and Use of Proton Pump Inhibitors COMPUS Interim Report CCOHTA March 6, 2006 Note that the information presented in this document does not constitute recommendations
More informationFamotidine Extended Abstracts
Famotidine Extended Abstracts I) Primary literature Summary Ciccone, Decktor, et. al. Efficacy and tolerability of famotidine in preventing heartburn and related symptoms of upper gastrointestinal discomfort.
More informationQUICK QUERIES. Topical Questions, Sound Answers
QUICK QUERIES Topical Questions, Sound Answers Dyspepsia: An Evidence-Based Approach Alan B. R. Thomson, MD, PhD, FRCPC, FACP, FACG Presented at the University of Alberta s Medical Grand Rounds, University
More informationCOMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION
Phil J Gastroenterol 2006; 2: 25-29 COMPARISON OF ONCE-A-DAY VERSUS TWICE-A-DAY CLARITHROMYCIN IN TRIPLE THERAPY FOR HELICOBACTER PYLORI ERADICATION Marianne P Collado, Ma Fatima P Calida, Peter P Sy,
More informationGilles Jequier. Commercial Director Organobalance, a Novozymes Company
"Latest clinical Evidences showing that a proprietary Lactobacillus reuteri Strain can reduce the Symptoms associated with a Helicobacter pylori Infection" Gilles Jequier Commercial Director Organobalance,
More informationProton Pump Inhibitor De-prescribing Guidance
Amendment History Proton Pump Inhibitor De-prescribing Guidance VERSION DATE AMENDMENT HISTORY 1.0 2013 Previous version 2.0 September 2015 Comments Amendment to Flow chart and addition of Rationale page
More informationPLANNING COMMITTEE. Seek simplicity, and mistrust it. Alfred North Whitehead
PLANNING COMMITTEE 1. Content Experts Clinical experts Desmond Leddin MB FRCPC, Head, Division of Gastroenterology, Dalhousie University Drug evaluation pharmacist Pam McLean-Veysey BScPharm, Drug Evaluation
More informationBleeds in Cardiovascular Disease
Preventing Gastrointestinal Bleeds in Cardiovascular Disease Patients t on Aspirin i Joel C. Marrs, Pharm.D., BCPS Clinical Assistant Professor OSU/OHSU College of Pharmacy Pharmacy Practice IX (PHAR 766)
More informationOne-third of adults experience pain or discomfort in
GASTROENTEROLOGY 2002;122:1270 1285 Dyspepsia Management in Primary Care: A Decision Analysis of Competing Strategies BRENNAN M. R. SPIEGEL,* NIMISH B. VAKIL, and JOSHUA J. OFMAN*, *Department of Medicine
More informationProton Pump Inhibitors. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.01 Subject: Proton Pump Inhibitors Page: 1 of 6 Last Review Date: June 24, 2015 Proton Pump Inhibitors
More informationPharmacoeconomic analysis of proton pump inhibitor therapy and interventions to control Helicobacter pylori infection Klok, Rogier Martijn
University of Groningen Pharmacoeconomic analysis of proton pump inhibitor therapy and interventions to control Helicobacter pylori infection Klok, Rogier Martijn IMPORTANT NOTE: You are advised to consult
More informationTECHNOLOGY OVERVIEW. Issue 6 February Economic Assessment: Celecoxib and Rofecoxib for Patients with Osteoarthritis or Rheumatoid Arthritis
TECHNOLOGY OVERVIEW Issue 6 February 2002 Economic Assessment: Celecoxib and Rofecoxib for Patients with Osteoarthritis or Rheumatoid Arthritis Publications can be requested from: CCOHTA 110-955 Green
More informationORIGINAL INVESTIGATION. Effectiveness of Helicobacter pylori Therapies in a Clinical Practice Setting
ORIGINAL INVESTIGATION Effectiveness of Helicobacter pylori Therapies in a Clinical Practice Setting M. Brian Fennerty, MD; David A. Lieberman, MD; Nimish Vakil, MD; Nathan Magaret; Douglas O. Faigel,
More informationEDUCATION PRACTICE. Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? Clinical Scenario.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2008;6:1086 1090 EDUCATION PRACTICE Persistent Helicobacter pylori Infection After a Course of Antimicrobial Therapy What s Next? RICHARD J. SAAD* and WILLIAM D.
More informationDrug Class Review on Proton Pump Inhibitors
Drug Class Review on Proton Pump Inhibitors Final Report Update 4 July 2006 Original Report Date: November 2002 Update 1 Report Date: April 2003 Update 2 Report Date: April 2004 Update 3 Report Date: May
More informationTreatment of H. pylori Infection: The Reality
YALE JOURNAL OF BIOLOGY AND MEDICINE 71 (1998), pp. 119-124. Copyright 1999. All rights reserved. Treatment of H. pylori Infection: The Reality Nimish Vakil University of Wisconsin Medical School, Milwaukee
More informationBNF CHAPTER 1: GASTRO-INTESTINAL SYSTEM. 1 April 13
BNF CHAPTER 1: GASTRO-INTESTINAL SYSTEM 1 BNF 1.1 ANTACIDS Mucogel and Peptac are effective antacids and are available over the counter Gaviscon / Gaviscon Advance are available over the counter First
More informationAppropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist
Appropriate Use of Proton Pump Inhibitors (PPIs) Anderson Mabour, Pharm.D., BCPS Clinical Pharmacy Specialist Disclosures I have no actual or potential conflicts of interest to report in relation to this
More informationJune By: Reza Gholami
ACG/CAG guideline on Management of Dyspepsia June 2017 By: Reza Gholami DEFINITION OF DYSPEPSIA AND SCOPE OF THE GUIDELINE Dyspepsia was originally defined as any symptoms referable to the upper gastrointestinal
More informationAmerican College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection
American Journal of Gastroenterology ISSN 0002-9270 C 2007 by Am. Coll. of Gastroenterology doi: 10.1111/j.1572-0241.2007.01393.x Published by Blackwell Publishing American College of Gastroenterology
More informationPeptic Ulcer Disease and NSAIDs
Peptic Ulcer Disease and NSAIDs National Digestive Diseases Information Clearinghouse What is a peptic ulcer? A peptic ulcer is a sore on the inner lining of the stomach or duodenum the first part of the
More informationWhat Is Peptic Ulcer Disease?
What Is Peptic Ulcer Disease? Peptic ulcer disease is when painful sores form in the lining of the stomach, duodenum (start of the small intestine) or bowels. An ulcer can cause belly pain and, in some
More informationHealth technology Serological testing and endoscopy with biopsy for suspected peptic ulcer disease.
Immediate endoscopy or initial Helicobacter pylori serological testing for suspected peptic ulcer disease: estimating cost-effectiveness using decision analysis Fendrick A M, Chernew M E, Hirth R A, Bloom
More informationII. Angiotensin Receptor Blockers (ARBs) Drug Class Review
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE DOD BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32 C.F.R. 199.21,
More informationI. Kalfus MD, D. Riff MD, R. Fathi PhD, D. Graham MD
A Randomized Double Blind Placebo Controlled Phase III Study to Assess the Safety and Efficacy of Rifabutin Triple Therapy (RHB-105) for Helicobacter pylori (H. pylori) Infection in Dyspepsia Patients
More informationLow Dose Furazolidone for Eradication of H- pylori Instead of Clarithromycin: A Clinical Trial
Global Journal of Health Science; Vol. 7, No. 1; 2015 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Low Dose Furazolidone for Eradication of H- pylori Instead of
More informationRpts. GENERAL General Schedule (Code GE)
Pantoprazole 20mg Name, Restriction, Manner of administration and form Pantoprazole 20mg enteric tablet, 30 (8399C) Gastro-oesophageal reflux disease Name, Restriction, Manner of administration and form
More informationPharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network metaanalysis
Xin et al. BMC Gastroenterology (2016) 16:80 DOI 10.1186/s12876-016-0491-7 RESEARCH ARTICLE Open Access Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews
More informationFigure 1. Esophagitis healing rates at 4 and 8 weeks: PPI vs PPI (% risk difference) Lansoprazole 30mg vs Omeprazole 20mg, 4 weeks
Figure 1. Esophagitis healing rates at 4 and 8 weeks: PPI vs PPI (% risk difference) Healing rate difference at 4 weeks Esomeprazole 40mg vs Omeprazole 20mg Lansoprazole 15mg vs Omeprazole 20mg Richter,
More informationOne-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers
Aliment Pharmacol Ther 1997; 11: 89 93. One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers J. LABENZ*, J.-P. IDSTRO M, B. TILLENBURG*,
More informationHelicobacter Pylori Testing HELICOBACTER PYLORI TESTING HS-131. Policy Number: HS-131. Original Effective Date: 9/17/2009
Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.209 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationPolicy Evaluation: Proton Pump Inhibitors (PPIs)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationHelicobacter pylori: Diagnosis, treatment and risks of untreated infection
Helicobacter pylori: Diagnosis, treatment and risks of untreated infection Klaus Mönkemüller Department of Gastroenterology, Hepatology und Infectius Diseases Otto-von-Guericke University, Magdeburg bb
More informationTEXAS VENDOR DRUG PROGRAM
1 OF 12 Publication History o Revised March 2015; June 2013; November 2011; September 2011; September 20009; June 2009; December 2005; November 2003; October 2002. o Developed December 2001. Prepared by
More informationREAD THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. lansoprazole delayed-release capsule (Manufacturer s standard)
READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr PREVACID lansoprazole delayed-release capsule (Manufacturer s standard) Read this carefully before you start taking
More information